Home › Bladder Cancer
Bladder Cancer clinical trials recruiting in the U.S.
142 studies for Bladder Cancer are recruiting participants at sites across the United States.
Bladder cancer symptoms range from lower back pain to blood in your urine. Read about important risk factors and find a list of treatments available
Cities with the most studies
- New York City, NY34 studies
- Nashville, TN31 studies
- Houston, TX31 studies
- Boston, MA27 studies
- Dallas, TX27 studies
- Washington, DC26 studies
- Los Angeles, CA24 studies
- Baltimore, MD24 studies
- St. Louis, MO22 studies
- Edison, NJ22 studies
- Seattle, WA21 studies
- Philadelphia, PA21 studies
- Chicago, IL21 studies
- Durham, NC20 studies
- Cleveland, OH18 studies
- Columbus, OH18 studies
- Queens, NY16 studies
- Atlanta, GA15 studies
- Baldwin Park, CA14 studies
- Portland, OR13 studies
- San Antonio, TX13 studies
- Austin, TX12 studies
- Grand Rapids, MI12 studies
- Orange, CA12 studies
- San Francisco, CA12 studies
- Rochester, MN12 studies
- Kansas City, KS12 studies
- San Diego, CA11 studies
- Denver, CO11 studies
- Oklahoma City, OK11 studies
- Staten Island, NY11 studies
- Irvine, CA11 studies
- Detroit, MI11 studies
- New Rochelle, NY11 studies
- Minneapolis, MN11 studies
- Birmingham, AL11 studies
- Cincinnati, OH10 studies
- Salt Lake City, UT10 studies
- Kansas City, MO10 studies
- Omaha, NE10 studies
By state
- Alabama11 studies
- Alaska3 studies
- Arizona20 studies
- Arkansas15 studies
- California53 studies
- Colorado20 studies
- Connecticut10 studies
- Delaware4 studies
- District of Columbia17 studies
- Florida38 studies
- Georgia18 studies
- Idaho6 studies
- Illinois30 studies
- Indiana14 studies
- Iowa12 studies
- Kansas17 studies
- Kentucky7 studies
- Louisiana13 studies
- Maryland36 studies
- Massachusetts32 studies
- Michigan25 studies
- Minnesota24 studies
- Mississippi3 studies
- Missouri27 studies
- Montana7 studies
- Nebraska11 studies
- Nevada4 studies
- New Hampshire3 studies
- New Jersey26 studies
- New Mexico3 studies
- New York40 studies
- North Carolina26 studies
- North Dakota4 studies
- Ohio36 studies
- Oklahoma12 studies
- Oregon14 studies
- Pennsylvania27 studies
- Rhode Island4 studies
- South Carolina16 studies
- South Dakota4 studies
- Tennessee34 studies
- Texas51 studies
- Utah14 studies
- Vermont3 studies
- Virginia24 studies
- Washington25 studies
- West Virginia5 studies
- Wisconsin17 studies
- Wyoming3 studies
Recently updated studies
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT03866382DK222 Study at Hopkins
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07140315Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07061964A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06833073Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07421700A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07206225En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Sep 28, 2026 · NCT04235764A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277413Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06770582A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06172478DESTINY-PANTUMOUR04
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07419295Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
RecruitingPhase 1/2
Ages 18 to 99 · All sexes · Updated Sep 22, 2026 · NCT06814496A Study of Surgical Techniques During Cystectomy
RecruitingPhase 3
Ages 21 and older · All sexes · Updated Sep 22, 2026 · NCT06703476A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218380Prehabilitation in High-risk Oncologic Surgery
Recruiting
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07638410Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT06529822Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05267626A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06733363Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07667335Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06394570A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07217171ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07566156A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07222488From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.